3D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol, 2003, 23:117-134.
4Melvin, SM. The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis. Ren Fail. 2000,22:663-684.
5Barisoni L, Kriz W, Mundel P,et al. The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-Associated nephropathy. J Am Soc Nephrol, 1999,10:51-61.
6Sharif K, Goyal M, Kershaw D, et al. Podocyte phenotypes as defined by expression and distribution of GLEPP1 in the developing glomerulus and in nephrotic glomeruli from MCD, CNF, and FSGS. A dedifferentiation hypothesis for the nephrotic syndrome. Exp Nephrol, 1998,6:234-244.
7Thomas PE, Wharram BL, Goyal M, et al. GLEPP-1, a renal glomerular epithelial (podocyte) membrane protein-tyrosine phosphatase: Identification, molecular cloning, and characterization in rabbit. J Biol Chem, 1994,269:19953-19962.
8Appay MD, Mounier F, Gubler MC, et al. Ontogenesis of the glome- rular C3b receptor (CR1) in fetal human kidney. Clin Immunol Immunopathol, 1985,37:103-113.
9Schwartz MM. The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis. Renal Failure,2000,22: 663-667.
9Liu H,Liu ZH,Chen ZH,et al.Triptolide:a potent inhibitor of NF-kappa B in T-lymphocytes[J].Acta Pharmacol Sin,2000,21 (9):782-786.
10Qiu D,Kao PN.Immunosuppressive and anti-inflammatory mechanisms of triptolide,the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook[J].Drugs in R D,2003,4(1):1-18.
